Patents Assigned to Hitgen INC.
-
Patent number: 11702391Abstract: The present disclosure relates to compounds of Formula I: that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.Type: GrantFiled: March 23, 2022Date of Patent: July 18, 2023Assignees: BIOAGE LABS, INC., HITGEN, INC.Inventors: George Hartman, Xu He, Jia Du, Lifang Zhang, Paul Humphries, Kevin Edward Leif Wilhelmsen
-
Patent number: 11584759Abstract: Disclosed is a macrocyclic kinase inhibitor, wherein the compound, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is as shown in formula I. Experiments show that the new compound as shown in formula I disclosed in the present invention exhibits an excellent TRK inhibitory activity, has a significant inhibitory effect on TRKA-mutant cell growth, and exhibits an excellent inhibitory effect on in vivo tumor growth, thus providing a new choice for the clinical treatment of diseases associated with abnormal TRK activity.Type: GrantFiled: April 17, 2019Date of Patent: February 21, 2023Assignee: HITGEN INC.Inventors: Jin Li, Dengyou Zhang, Jingchao Feng, Zhi Wang, Leichang Pan, Jing Hu, Wei Chen
-
Publication number: 20220119379Abstract: The present application discloses a compound depicted by formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound provided in the present application can bind effectively to STING and has a good agonistic action on STING protein, and exhibits a good inhibitory effect on multiple tumors. Thus, the compound provided in the present application serves as a STING agonist and can be used for treating various related conditions. The compound provided in the present invention shows a very promising prospect for application thereof in the preparation of a medicament for treating a disease associated with STING activity (in particular, a medicament for treating an inflammatory disease, an allergic disease, an autoimmune disease, an infectious disease, a cancer or a precancerous syndrome) and in the preparation of an immune adjuvant, providing a novel option for clinically screening and/or preparing drugs for diseases associated with STING activity.Type: ApplicationFiled: January 21, 2020Publication date: April 21, 2022Applicant: HITGEN INC.Inventors: Jin LI, Dengyou ZHANG, Fei PAN, Rong MA, Wenji ZHU, Yanfei XIN, Si LI, Weiping LIU, Yanping LIN
-
Patent number: 11078161Abstract: Disclosed herein are a compound of formula (I) and a preparation method and uses thereof. The compound shows a good inhibitory activity against ROCK, providing a new medicinal strategy to clinically treat the diseases associated with abnormal ROCK activity.Type: GrantFiled: December 16, 2019Date of Patent: August 3, 2021Assignee: HITGEN INC.Inventors: Jin Li, Dengyou Zhang, Jingchao Feng, Wei Liao, Li Lin, Si Li
-
Publication number: 20210147443Abstract: Disclosed is a macrocyclic kinase inhibitor, wherein the compound, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is as shown in formula I. Experiments show that the new compound as shown in formula I disclosed in the present invention exhibits an excellent TRK inhibitory activity, has a significant inhibitory effect on TRKA-mutant cell growth, and exhibits an excellent inhibitory effect on in vivo tumor growth, thus providing a new choice for the clinical treatment of diseases associated with abnormal TRK activity.Type: ApplicationFiled: April 17, 2019Publication date: May 20, 2021Applicant: HITGEN INC.Inventors: Jin LI, Dengyou ZHANG, Jingchao FENG, Zhi WANG, Leichang PAN, Jing HU, Wei CHEN
-
Patent number: 10801022Abstract: The present invention provides a method of solid-phase synthesis of DNA-encoded compound library. The method includes following steps: a) reacting solid carrier G-1 with linker molecule L-1 to prepare L-G-1; b) reacting DNA with linker molecule L-0 to prepare L-2; c) reacting L-G-1 with L-2 to prepare L-G-2; d) removing protection group of the L-G-2 and obtaining L-G-2-1; e) reacting the L-G-2-1 with synthetic building block and performing DNA encoding; and f) removing the solid carrier and obtaining the DNA-encoded compound library. Compared with the prior art, the present invention can complete post-treatment purification of the reaction only by filtration and irrigation processes for several times. The present invention is simple to operate, can shorten the production cycle of DNA encoded compound library with more than 50%, significantly increases the production efficiency and the unicity as well as the purity of the final products.Type: GrantFiled: October 13, 2017Date of Patent: October 13, 2020Assignee: Hitgen INC.Inventors: Jin Li, Jinqiao Wan, Guansai Liu, Dengfeng Dou